{"id":"W3008798432","doi":"10.1016/j.ejca.2020.01.008","title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Canada; Janssen Pharmaceuticals; Merck Sharp and Dohme; NeraCare; Sun Pharma; Universidad de Cantabria; ZonMw; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares; Vertex Pharmaceuticals; Mylan; Regeneron Pharmaceuticals; Eisai Korea; Agence Nationale de la Recherche; F. Hoffmann-La Roche; Millennium Challenge Corporation; Università Degli Studi di Modena e Reggio Emila; Immunocore; Novartis Pharma; AbbVie; Novartis; Celgene; Pfizer; Biogen; Arthrex GmbH; LEO Pharma; LEO Pharma Research Foundation; Wyeth; Janssen Biotech; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Roche; Merck; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Leo Baeck Institute; Bristol-Myers Squibb; Amgen; Meadows Foundation; EMD Serono; Almirall; Galderma; BioNTech","keywords":"Medicine; Cetuximab; Systemic therapy; Radiation therapy; Guideline; Oncology; Lymph node; Internal medicine; Cancer; Dissection (medical); Surgery; Pathology; Colorectal cancer; Breast cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059883,0.001217745,0.001352852,0.003529924,0.0005464916,0.00160191,0.002358267,0.002951664,0.01219703],"category_scores_gemma":[0.003425511,0.0004816885,0.001830392,0.002623118,0.0005578179,0.001213265,0.001408612,0.002903903,0.01129106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002006822,"about_ca_system_score_gemma":0.004711735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006865829,"about_ca_topic_score_gemma":0.01020981,"domain_scores_codex":[0.9983956,0.0004991777,0.0002901369,0.0001018838,0.0005846825,0.0001284582],"domain_scores_gemma":[0.9982656,0.0003716306,0.0002300783,0.00006149483,0.0009436089,0.0001277295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004406963,0.00007088895,0.0002634772,0.005777286,0.0000539663,0.0004714599,0.0001151618,0.0008626478,0.000823123,0.002594872,0.7089803,0.2799427],"study_design_scores_gemma":[0.00004080728,0.00002448069,0.0006331647,0.006593233,0.00005715152,0.001021189,0.00003548595,0.000157682,0.0001234863,0.001156102,0.9901426,0.00001459438],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.001641659,0.7528319,0.0116174,0.04448854,0.01524809,0.002886776,0.01427109,0.0008868179,0.1561276],"genre_scores_gemma":[0.01272882,0.7278246,0.04894311,0.05644828,0.005599733,0.005177408,0.0585169,0.0004440393,0.08431716],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01219703,"threshold_uncertainty_score":0.04080307,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03598642157108808,"score_gpt":0.2937085446046721,"score_spread":0.257722123033584,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}